Zacks.com Announces That Nadine Wong Highlights: Discovery Laboratories.CHICAGO -- Nadine Wong, editor of the BioTech Stock Report newsletter, says Discovery Laboratories (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :DSCO DSCO Deep Space Climate Observatory ) has significant potential in treating respiratory diseases. Click here for the full story exclusively on Zacks.com: http://at.zacks.com/?id=84 Highlights from the August 8th Featured Expert column by Nadine Wong include: Breathing Easy - Discovery Laboratories Discovery Laboratories (NASDAQ:DSCO) develops humanized lung surfactant Surfactant Definition Surfactant is a complex naturally occurring substance made of six lipids (fats) and four proteins that is produced in the lungs. It can also be manufactured synthetically. as a surfactant replacement therapy surfactant replacement therapy Neonatology Intratracheally administered bronchoalveolar fluid derived from calves–98% lipids, comprised of 90% phospholipid, especially dipalmitoyl-phosphatidylcholine and 2% apoproteins, which markedly improves gas exchange in (SRT (1) (Source Routing Transparent) An IEEE-standard that provides bridging between Ethernet and Token Ring networks. Ethernet LANs use transparent bridging, and Token Ring LANs use source route bridging (SRB). ) for respiratory diseases. Back in February 2005, Discovery's Surfaxin received an approvable letter by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. for the treatment of respiratory distress syndrome respiratory distress syndrome or hyaline membrane disease Common complication in newborns, especially after premature birth. Symptoms include very laboured breathing, bluish skin tinge, and low blood oxygen levels. (RDS (1) (Remote Data Services) A set of programming interfaces from Microsoft that enables users to update data on the Internet or intranets from their ActiveX-enabled browser. ) in premature babies. But its share price took a hit as there was quality assurance issues associated with its manufacturing facility. The deficiencies were mainly related to basic quality control, process assurance and documentation requirements to support the commercial production process. In Nadine Wong and her team's opinion, the reaction was overly harsh. Since then, the stock has been making a comeback in anticipation of a strong response by the company. However, on July 29, 2005, the stock took another hit in response to the Discovery submitting additional information to the FDA in order to receive final approval for Surfaxin. A reasonable explanation for the sudden raise and pullback Pullback A falling back of a price from its peak. This type of price movement might be seen as a brief reversal of the prevailing upward trend, signaling a slight pause in upward momentum. in Discovery's share price is that it's trading in line with the overall biotech sector and not due to the concerns over the production of Surfaxin. The market appears to realize the significant potential of Discovery's follow-on SRT technologies. Besides, Surfaxin has clinically demonstrated safety and efficacy advantages over existing products in the U.S. and Europe. The fact that FDA allows Discovery to use the comparison data with existing treatments will assist Discovery sales and its marketing force to convince doctors to switch. Read Nadine Wong's complete commentary by clicking: http://at.zacks.com/?id=85 About Zacks Featured Experts Successful investing requires professional advice from knowledgeable experts who can help investors achieve their financial goals in good markets and improve their portfolios, especially in bad ones. That is why Zacks Investment Research Zacks Investment Research A firm that compiles earnings estimates and brokerage firm investment recommendations for thousands of publicly traded firms. has assembled the best investment experts in the business to offer their powerful advisory newsletters on all the major investment topics: Stocks, Mutual Funds, Bonds, Options, Futures etc. Additional recommendations from Zacks.com Featured Experts are highlighted in the free investment newsletter, Profit from the Pros. Each issue highlights several Featured Experts in this free e-mail See Internet e-mail service. newsletter. Register for a free subscription to "Profit from the Pros" at: http://at.zacks.com/?id=86 About Zacks Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 to compile, analyze, and distribute investment research to both institutional and individual investors. The guiding principle behind Zacks work is the belief that investment experts, such as brokerage analysts and investment newsletter writers, have superior knowledge about how to invest successfully. The goal is to unlock these pros' profitable insights for individual investors hard-pressed to find this valuable information in one source. A free subscription to "Profit from the Pros" weekly e-mail newsletter provides the best way to use these experts' insights for more profitable investing. Register now for a free subscription to the Profit from the Pros newsletter at http://at.zacks.com/?id=87 Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion